HUTCHMED (China) Limited (NASDAQ: HCM) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 4.58 | EPS (ttm) | 2.73 | Insider Own | 0.10% | Shs Outstand | 174.47M | Perf Week | 12.40% |
| Market Cap | 2.16B | Forward P/E | 36.04 | EPS next Y | 0.35 | Insider Trans | 0.00% | Shs Float | 170.46M | Perf Month | 13.93% |
| Enterprise Value | 2.18B | PEG | 0.00 | EPS next Q | - | Inst Own | 2.49% | Short Float | 0.11% | Perf Quarter | -6.01% |
| Income | 39.49M | P/S | 3.93 | EPS this Y | -91.41% | Inst Trans | - | Short Ratio | 4.04 | Perf Half Y | -14.14% |
| Sales | 548.52M | P/B | 20.22 | EPS next Y | 55.44% | ROA | 26.06% | Short Interest | 193.90K | Perf YTD | -6.15% |
| Book/sh | - | P/C | - | EPS next 5Y | 51.29% | ROE | 37.04% | 52W High | 18.36 -31.64% | Perf Year | -30.23% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -2.35% | 52W Low | 9.80 28.05% | Perf 3Y | -11.78% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 8.89% 19.26% | Gross Margin | 11.64% | Volatility | 2.31% 2.17% | Perf 5Y | -70.25% |
| Dividend TTM | - | EV/Sales | 3.98 | EPS Y/Y TTM | 1081.82% | Oper. Margin | -7.14% | ATR (14) | 0.36 | Perf 10Y | -4.58% |
| Dividend Ex-Date | - | Quick Ratio | 4.83 | Sales Y/Y TTM | -13.02% | Profit Margin | 83.30% | RSI (14) | 67.60 | Recom | 2.30 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.96 | EPS Q/Q | 1658.42% | SMA20 | 10.40% | Beta | 0.26 | Target Price | 13.80 |
| Payout | 0.00% | Debt/Eq | 0.08 | Sales Q/Q | -16.67% | SMA50 | 13.36% | Rel Volume | 0.84 | Prev Close | 12.51 |
| Employees | 1,796 | LT Debt/Eq | 0.06 | Earnings | Mar 04 | SMA200 | -7.21% | Avg Volume | 51.69K | Price | 12.55 |
| IPO Date | Mar 16, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 510.16% 142.38% | Net Debt/EBITDA | -1.03 | Volume | 43,352 | Change | 0.32% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-23-26 | Reiterated | Goldman Sachs | Neutral | $14 |
| May-28-26 | Reiterated | Morgan Stanley | Underweight | $18 → $14 |
| Sep-22-25 | Downgrade | Morgan Stanley | Equal Weight → Underweight | |
| May-14-24 | Reiterated | Morgan Stanley | $18 | |
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy | |
| Sep-22-21 | Downgrade | Goldman Sachs | Buy → Neutral |
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 548 | 550 | 630 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 548 | 337 | 348 | — | — | — | — | — | — | |
| Gross Profit | 2 | 213 | 283 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 108 | 103 | 113 | — | — | — | — | — | — | |
| Research and Development | 160 | 164 | 213 | — | — | — | — | — | — | |
| Other Operating Expense | -232 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -36 | -55 | -44 | — | — | — | — | — | — | |
| Interest Expense | 0 | 3 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 54 | 580 | 92 | — | — | — | — | — | — | |
| Net Income Before Taxes | 20 | 523 | 45 | — | — | — | — | — | — | |
| Income Taxes | 2 | 64 | 7 | — | — | — | — | — | — | |
| Consolidated Net Income | 18 | 458 | 38 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 18 | 459 | 38 | — | — | — | — | — | — | |
| Net Income | 18 | 458 | 38 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.10 | 2.65 | 0.22 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.10 | 2.65 | 0.22 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.10 | 2.60 | 0.22 | — | — | — | — | — | — | |
| EBITDA | -20 | -41 | -31 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 125.50 | 5.13 | 65.50 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.96 | 4.17 | 3.91 | — | — | — | — | — | — | |
| Gross Margin | 0.36 | 38.73 | 44.92 | — | — | — | — | — | — | |
| Operating Margin | -6.57 | -10.00 | -6.98 | — | — | — | — | — | — | |
| Net Margin | 3.28 | 83.27 | 6.03 | — | — | — | — | — | — | |
| Shares Outstanding | 173 | 172 | 171 | — | — | — | — | — | — | |
| Market Capitalization | 2,171 | 2,293 | 2,464 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |